Thomas Tuschl

This inventor holds 77 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 33 EPO patents, primarily in RNA Interference (CPC class C12N). Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , The Rockefeller University, Massachusetts Institute of Technology. Active years: 2006-2026.

USPTO Granted Patents = 77 (Patent Applications = 7)

% Patents Active = 33.8

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 33 (Patent Applications = 37)

Average Co-Inventor Count = 3.8

ph-index = 27

Forward Citations = 2,043(Granted Patents)

Forward Citations (Not Self Cited) = 1,845(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Goettingen, DE (2013 - 2015)
Brooklyn, NY (US) (2012 - 2021)
New York, NY (US) (2006 - 2022)

Company Filing History:

43 out of 1,327

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

33 out of 750

The Rockefeller University

patents

24 out of 8,568

Massachusetts Institute of Technology

patents

4. 24 out of 1,623

University of Massachusetts

patents

5. 24 out of 317

Whitehead Institute for Biomedical Research

patents

6. 6 out of 615

Memorial Sloan Kettering Cancer Center

patents

7. 5 out of 1,492

Rutgers, The State University of New Jersey

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

RNA Interference

Small RNA Molecules

Second Messenger Signaling

cGAS Inhibitors

MicroRNA

RNA Isolation

RNA-Binding Proteins

Nucleic Acids

RNA Ligase

Autoinflammatory Diseases

Cancer Metastasis

STING Modulators

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12522603 - Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis (2026-01-13),

2. 11414422 - Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS (2022-08-16),

3. 11014956 - Compositions and methods for altering second messenger signaling (2021-05-25),

4. 10968443 - Method of RNA isolation from clinical samples (2021-04-06),

5. 10633656 - RNA interference mediating small RNA molecules (2020-04-28),

6. 10472625 - RNA sequence-specific mediators of RNA interference (2019-11-12),

7. 10385091 - Compositions and methods for altering second messenger signaling (2019-08-20),

8. 10176292 - STING crystals and modulators (2019-01-08),

9. 10131686 - Compositions and methods for altering second messenger signaling (2018-11-20),

10. 10023865 - RNA-interference by single-stranded RNA molecules (2018-07-17),

11. 9840533 - Compositions and methods for altering second messenger signaling (2017-12-12),

12. 9567582 - RNA interference mediating small RNA molecules (2017-02-14),

13. 9550993 - Identification of novel genes coding for small temporal RNAs (2017-01-24),

14. 9476048 - DNA virus MicroRNA and methods for inhibiting same (2016-10-25),

15. 9476044 - RNA-interference by single-stranded RNA molecules (2016-10-25),

Certainly! Here is the article about inventor Thomas Tuschl:

Title: Unveiling the Success Story of Inventor Thomas Tuschl

Introduction:

In the realm of innovation, one name shines brightly - Thomas Tuschl. Hailing from New York, NY (US), this prolific inventor has made remarkable contributions in the field of biotechnology and pharmaceuticals.

Latest Patents:

With an impressive portfolio of 50 patents under his belt, Thomas Tuschl's latest patents truly demonstrate his groundbreaking work. His inventions include Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS and compositions for altering second messenger signaling, offering promising therapeutic avenues for cGAS-related autoimmune diseases.

Career Highlights:

Thomas Tuschl's journey towards innovation is adorned with significant milestones. Having worked at prestigious institutions like The Rockefeller University and Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., he has honed his expertise in molecular biology and drug discovery.

Collaborations:

Collaboration has been a cornerstone of Thomas Tuschl's success. Along his path of discovery, he has worked closely with esteemed colleagues such as Winfried Lendeckel and Reinhard Rauhut. Together, they have pushed the boundaries of scientific exploration, leading to remarkable inventions.

Conclusion:

In conclusion, Thomas Tuschl's dedication to innovation and relentless pursuit of scientific excellence have culminated in a legacy of patents that not only redefine the landscape of biotechnology but also offer hope for new therapeutic interventions. His contributions continue to inspire generations of inventors and researchers, promising a future bright with possibilities in the world of science and technology.